Blinatumomab, a CD3/CD19 BiTE, has notably improved outcomes for pediatric patients with relapsed or refractory (R/R) B-ALL and is now a frontline treatment option (101, 102). Here, CD19 is linked to acute lymphoblastic leukemia.